Health & Fitness
Health and Fitness
Health and Fitness
Thu, November 18, 2010
NanoViricides CEO to Present at the ProactiveInvestors One2One Forum in New York City
WEST HAVEN, Conn.--([ BUSINESS WIRE ])--NanoViricides, Inc. (OTC BB: NNVC) (the "Company"), reports that Dr. Eugene Seymour, MD, MPH, the Companya™s CEO, will be presenting at the One2One Investors Forum organized by ProactiveInvestors. This forum is being held at the International Barclays Hotel in New York City from 5pm to 6:30pm today ([ http://www.proactiveinvestors.com/register/event_details/27 ]).
Dr. Seymour will present a Company Overview in front of a targeted global investors audience as per ProactiveInvestors. NanoViricides, Inc. is one of the sponsors of this event.
The Company now has five commercially important drugs in its pipeline, targeting a total market size of approximately $40 Billion. These drugs target HIV, all Influenzas, viral diseases of the external Eye, Herpes Simplex viral infections including cold sores and genital herpes (HSV), and Dengue viruses. The Company has recently released data that demonstrate a profound effectiveness of FluCide in a high infection, lethal animal study.
[ About NanoViricides ]:
[ NanoViricides, Inc. ] ([ www.nanoviricides.com ]) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are aforward-looking statementsa within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
